• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

使用高效液相色谱-质谱联用技术测定乳腺癌患者中4-羟基雄甾-4-烯-3,17-二酮的代谢情况。

Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry.

作者信息

Poon G K, Jarman M, Rowlands M G, Dowsett M, Firth J

机构信息

Cancer Research Campaign Laboratory, Institute of Cancer Research, Sutton, Surrey, U.K.

出版信息

J Chromatogr. 1991 Apr 19;565(1-2):75-88. doi: 10.1016/0378-4347(91)80372-j.

DOI:10.1016/0378-4347(91)80372-j
PMID:1874906
Abstract

A sensitive procedure for studying the metabolism of the steroidal aromatase inhibitor 4-hydroxy-androst-4-ene-3,17-dione (4OHA) was developed based on enzyme hydrolysis, liquid-liquid extraction and reversed-phase liquid chromatography coupled with a mass spectrometer (LC-MS) using a thermospray interface. Seven metabolites were identified from the hydrolysed urine samples together with the parent drug. The major routes of metabolism were via dehydrogenation, reduction of the ketone functional groups, reduction at the C-4-C-5 double bond and hydroxylation at the C-5 position. Confirmation of the identity of 4OHA and its metabolites isolated from female patients' urine samples was accomplished by comparison of the retention times of their corresponding synthetic standards on LC-MS. We have demonstrated that this technique is particularly suitable for studying the metabolism of steroidal drugs.

摘要

基于酶水解、液-液萃取以及使用热喷雾接口的反相液相色谱与质谱联用(LC-MS)技术,开发了一种用于研究甾体芳香酶抑制剂4-羟基雄甾-4-烯-3,17-二酮(4OHA)代谢的灵敏方法。从水解后的尿液样本中鉴定出了七种代谢物以及母体药物。主要代谢途径包括脱氢、酮官能团的还原、C-4-C-5双键处的还原以及C-5位的羟基化。通过比较4OHA及其从女性患者尿液样本中分离出的代谢物与相应合成标准品在LC-MS上的保留时间,确认了它们的身份。我们已经证明该技术特别适用于研究甾体药物的代谢。

相似文献

1
Determination of 4-hydroxyandrost-4-ene-3,17-dione metabolism in breast cancer patients using high-performance liquid chromatography-mass spectrometry.使用高效液相色谱-质谱联用技术测定乳腺癌患者中4-羟基雄甾-4-烯-3,17-二酮的代谢情况。
J Chromatogr. 1991 Apr 19;565(1-2):75-88. doi: 10.1016/0378-4347(91)80372-j.
2
Investigation of conjugated metabolites of 4-hydroxyandrost-4-ene-3,17-dione in patient urine by liquid chromatography-atmospheric pressure ionization mass spectrometry.采用液相色谱-大气压电离质谱法对患者尿液中4-羟基雄甾-4-烯-3,17-二酮的结合代谢物进行研究。
Drug Metab Dispos. 1992 Nov-Dec;20(6):941-7.
3
Identification of 4-hydroxyandrost-4-ene-3,17-dione metabolites in prostatic cancer patients by liquid chromatography-mass spectrometry.采用液相色谱-质谱联用技术鉴定前列腺癌患者体内4-羟基雄甾-4-烯-3,17-二酮的代谢产物
J Chromatogr. 1992 May 8;576(2):235-44. doi: 10.1016/0378-4347(92)80197-x.
4
Metabolic studies of formestane in horses.马体内福美斯坦的代谢研究。
Drug Test Anal. 2013 Jun;5(6):412-9. doi: 10.1002/dta.1444. Epub 2013 Jan 21.
5
Quantitative analysis of androst-4-ene-3,6,17-trione and metabolites in human urine after the administration of a food supplement by liquid chromatography/ion trap-mass spectrometry.采用液相色谱/离子阱质谱法对食用一种食品补充剂后人体尿液中的雄甾-4-烯-3,6,17-三酮及其代谢产物进行定量分析。
J Chromatogr B Analyt Technol Biomed Life Sci. 2005 Dec 15;828(1-2):21-6. doi: 10.1016/j.jchromb.2005.08.024. Epub 2005 Oct 6.
6
Metabolism of the aromatase inhibitor 4-hydroxyandrostenedione in vivo. Identification of the glucuronide as a major urinary metabolite in patients and biliary metabolite in the rat.芳香化酶抑制剂4-羟基雄烯二酮的体内代谢。鉴定葡糖醛酸苷为患者尿液中的主要代谢物及大鼠胆汁中的代谢物。
J Steroid Biochem. 1986 Feb;24(2):619-22. doi: 10.1016/0022-4731(86)90128-7.
7
Metabolism of 4-hydroxyandrost-4-ene-3,17-dione by rat hepatocytes.大鼠肝细胞对4-羟基雄甾-4-烯-3,17-二酮的代谢
J Steroid Biochem. 1986 Feb;24(2):607-17. doi: 10.1016/0022-4731(86)90127-5.
8
Metabolism of 4-hydroxyandrostenedione and 4-hydroxytestosterone: Mass spectrometric identification of urinary metabolites.4-羟基雄烯二酮和4-羟基睾酮的代谢:尿代谢物的质谱鉴定
Steroids. 2007 Mar;72(3):278-86. doi: 10.1016/j.steroids.2006.11.018. Epub 2007 Jan 17.
9
Metabolism of the steroidal aromatase inhibitor atamestane in rats, cynomolgus monkeys and humans. Isolation and identification of the major metabolites.甾体芳香化酶抑制剂阿他美坦在大鼠、食蟹猴和人类中的代谢。主要代谢产物的分离与鉴定。
Eur J Drug Metab Pharmacokinet. 1994 Apr-Jun;19(2):137-50. doi: 10.1007/BF03188834.
10
Metabolism of boldenone in man: gas chromatographic/mass spectrometric identification of urinary excreted metabolites and determination of excretion rates.宝丹酮在人体内的代谢:气相色谱/质谱法鉴定尿中排泄的代谢物并测定排泄率。
Biol Mass Spectrom. 1992 Jan;21(1):3-16. doi: 10.1002/bms.1200210104.

引用本文的文献

1
Electrospray ionization mass spectrometry for analysis of low-molecular-weight anticancer drugs and their analogues.电喷雾电离质谱法分析低分子量抗癌药物及其类似物。
J Am Soc Mass Spectrom. 1993 Jul;4(7):588-95. doi: 10.1016/1044-0305(93)85020-X.
2
Clinical pharmacokinetics of aromatase inhibitors and inactivators.芳香化酶抑制剂和灭活剂的临床药代动力学
Clin Pharmacokinet. 2003;42(7):619-31. doi: 10.2165/00003088-200342070-00002.
3
Formestane. A review of its pharmacological properties and clinical efficacy in the treatment of postmenopausal breast cancer.
福美司坦。其治疗绝经后乳腺癌的药理特性及临床疗效综述。
Drugs Aging. 1996 Oct;9(4):292-306. doi: 10.2165/00002512-199609040-00006.
4
Second generation aromatase inhibitor--4-hydroxyandrostenedione.第二代芳香化酶抑制剂——4-羟基雄烯二酮。
Breast Cancer Res Treat. 1994;30(1):81-7. doi: 10.1007/BF00682742.
5
Formestane. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the management of breast cancer and prostatic cancer.福美司坦。对其药效学、药代动力学特性以及在乳腺癌和前列腺癌治疗中的潜在应用的综述。
Drugs. 1993 Jan;45(1):66-84. doi: 10.2165/00003495-199345010-00007.
6
Clinical pharmacokinetics of endocrine agents used in advanced breast cancer.晚期乳腺癌中使用的内分泌药物的临床药代动力学
Clin Pharmacokinet. 1992 May;22(5):327-58. doi: 10.2165/00003088-199222050-00002.